Volume 29, Issue 3
DOI: 10.24 205/03276716.2020.701
Detection of Circulating Tumour DNA in Early-Stage NSCLC Patients by a New Lung Cancer Targeted Sequencing Panel
Abstract
Circulating tumor DNA（ctDNA）derived from tumor cells carrying unique genetic information of tumor cells may enable a high specificity and noninvasive “liquid biopsy†for early diagnosis of cancer. Most previous studies have paid attention to ctDNA condition of advanced patients, and the dynamic changes of ctDNA during the treatment. Although small amount of research has focused on the early stage cancer patients, most of them used the next-generation sequencing panel, which include a lot of gene, and thousands of mutational hotspot site. It costs a lot and lack of pertinence. In this study, we constructed a small lung cancer targeted sequencing panel which only contains 13 genes, which consist of EGFR, KRAS, STK11, PDGFRA, CDKN2B-AS1, ALK, CTNNB1, RET, PTEN, NRAS, BRAF, TP53 and PIK3CA. Mutations in these genes are common in non-small-cell lung cancer (NSCLC) patients. In all NSCLC and early-stage patients, using our panel the mutation coverage was 84.1% and 85.5%, respectively. In 34 NSCLC patients, compare to the tumor biomarkers, the ctDNA is much sensitive (85.3% vs. 52.9%). For all of 64 patients, we conducted a 5year follow-up. We found that the patients, who were diagnosed at an early-stage, would have a good prognosis. This study demonstrates that our panel has potential clinical utility in the diagnosis and prognosis of lung cancer.
Keywords
circulating tumour DNA; tumour biomarkers; lung cancer targeted sequencing panel; 5-years survival.